Zacks Research Issues Optimistic Outlook for BHC Earnings

Bausch Health Companies Inc. (NYSE:BHC) – Equities researchers at Zacks Research raised their Q2 2025 EPS estimates for Bausch Health Companies in a report released on Tuesday, December 17th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $1.03 per share for the quarter, up from their prior estimate of $1.00. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.74 per share. Zacks Research also issued estimates for Bausch Health Companies’ FY2025 earnings at $4.28 EPS, Q1 2026 earnings at $1.09 EPS, Q2 2026 earnings at $1.14 EPS, Q3 2026 earnings at $1.37 EPS and FY2026 earnings at $5.05 EPS.

A number of other equities analysts have also recently issued reports on the stock. StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th. Finally, Royal Bank of Canada upped their price objective on Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $7.75.

Bausch Health Companies Stock Up 0.7 %

Bausch Health Companies stock opened at $7.39 on Thursday. The stock has a market cap of $2.67 billion, a price-to-earnings ratio of -15.40 and a beta of 0.69. The business’s 50-day simple moving average is $8.35 and its 200 day simple moving average is $7.27. Bausch Health Companies has a 12-month low of $3.96 and a 12-month high of $11.46.

Bausch Health Companies (NYSE:BHC) last announced its earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.10. The company had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.42 billion. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. Bausch Health Companies’s quarterly revenue was up 12.2% on a year-over-year basis. During the same period in the prior year, the business earned $1.03 earnings per share.

Institutional Trading of Bausch Health Companies

A number of large investors have recently made changes to their positions in BHC. Bfsg LLC grew its stake in Bausch Health Companies by 46.7% in the second quarter. Bfsg LLC now owns 11,450 shares of the company’s stock valued at $80,000 after acquiring an additional 3,643 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Bausch Health Companies by 6.9% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 60,706 shares of the company’s stock valued at $423,000 after purchasing an additional 3,923 shares during the period. Tobam increased its stake in Bausch Health Companies by 48.9% during the 2nd quarter. Tobam now owns 26,148 shares of the company’s stock worth $182,000 after purchasing an additional 8,586 shares in the last quarter. Van ECK Associates Corp raised its holdings in Bausch Health Companies by 3.9% during the 2nd quarter. Van ECK Associates Corp now owns 302,471 shares of the company’s stock worth $2,108,000 after buying an additional 11,379 shares during the period. Finally, CIBC Asset Management Inc lifted its position in Bausch Health Companies by 8.8% in the 2nd quarter. CIBC Asset Management Inc now owns 373,647 shares of the company’s stock valued at $2,604,000 after acquiring an additional 30,124 shares in the last quarter. Institutional investors own 78.65% of the company’s stock.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.